Core Viewpoint - The supervisory board of Jiangsu Jicui Yaokang Biotechnology Co., Ltd. held its 12th meeting of the second supervisory board on August 21, 2025, to review and approve several key proposals related to the company's financial and operational status for the first half of 2025, ensuring compliance with legal and regulatory requirements [1][2]. Group 1: Meeting Overview - The meeting was convened with all three supervisory board members present, along with some senior management personnel [1]. - The meeting adhered to the relevant laws and regulations, as well as the company's articles of association [1]. Group 2: Financial Reporting - The supervisory board approved the company's 2025 half-year report and its summary, confirming that the report accurately reflects the company's financial status and operational results for the first half of 2025 [2]. - The board's vote on this matter was unanimous, with 3 votes in favor and no opposition or abstentions [2]. Group 3: Fund Management - The board approved a special report on the management and actual use of raised funds for the first half of 2025, confirming that the management of these funds is legal and compliant [2]. - The vote on this report also received unanimous approval, with 3 votes in favor [2]. Group 4: Profit Distribution - The supervisory board reviewed and approved the profit distribution plan for the first half of 2025, which considers the company's profitability, cash flow, and funding needs, ensuring reasonable returns for shareholders [3]. - This proposal is subject to further review by the shareholders' meeting [3]. Group 5: Governance Changes - The board approved the proposal to cancel the supervisory board and amend the company's articles of association, aiming to enhance the governance structure in line with the latest legal requirements [4]. - This decision also received unanimous support from the board members [4]. Group 6: Governance System Updates - The board approved the addition and revision of certain governance systems to improve the company's operational compliance and governance structure [4]. - The vote on these updates was also unanimous, with 3 votes in favor [4]. Group 7: Fund Usage - The supervisory board approved the use of the company's own funds to pay for part of the investment projects, with plans to replace these with raised funds, thereby improving fund usage efficiency [5]. - This proposal was unanimously approved by the board members [5].

Core Viewpoint - The company plans to distribute a cash dividend of RMB 0.30 per 10 shares (including tax) based on its 2025 semi-annual financial performance, with a total cash dividend amounting to RMB 12,269,719.14, which represents 17.30% of the net profit attributable to shareholders for the period [1]. Summary by Sections Profit Distribution Plan - The company reported a net profit attributable to shareholders of RMB 70,905,477.14 for the first half of 2025, with the parent company's net profit at RMB 40,466,440.18 [1]. - As of June 30, 2025, the parent company's distributable profits amounted to RMB 353,380,864.98 [1]. - The total share capital as of June 30, 2025, was 410,000,000 shares, with 1,009,362 shares held in the repurchase account, leading to a base of 408,990,638 shares for the dividend distribution [1]. - The proposed cash dividend distribution will not include stock dividends or capital reserve transfers [1]. Decision-Making Process - The company's board of directors held a meeting on August 21, 2025, where the profit distribution plan was approved and deemed compliant with the company's profit distribution policy and shareholder return plan [2]. - The supervisory board also convened on the same day and approved the profit distribution plan, affirming that it considers the company's profitability, cash flow, and funding needs while ensuring reasonable returns for shareholders, particularly minority shareholders [3].

Group 1 - The board of directors of Jiangsu Jicui Yaokang Biotechnology Co., Ltd. held its 13th meeting of the second session on August 21, 2025, with all 9 directors present, including 3 independent directors [1] - The board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results [2] - The board also approved a special report on the management and actual use of raised funds for the first half of 2025, ensuring compliance with relevant laws and regulations [2] Group 2 - The board reviewed and approved the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement Action Plan for 2025," aimed at promoting sustainable development and protecting shareholder interests [3] - A profit distribution plan was approved, proposing a cash dividend of RMB 0.30 per 10 shares (tax included), with no stock dividends or capital reserve transfers [3] - The board decided to cancel the supervisory board and amend the company’s articles of association to enhance governance structure, which complies with legal requirements [4] Group 3 - The board approved the addition and revision of certain governance systems to further improve the company's governance structure and ensure compliance with relevant laws [5] - A proposal to supplement a non-independent director to the board and adjust the strategic committee was approved, with the candidate being Mr. Liu Dan [6] - The board agreed to use its own funds to pay for certain project expenses and later replace these with raised funds, ensuring financial flexibility [6] Group 4 - The board proposed to convene the second extraordinary general meeting of 2025 to discuss the relevant proposals [7]

Core Viewpoint - The company announced the approval of a proposal to use its own funds to pay for part of the investment project costs, which will later be replaced with raised funds, ensuring the normal progress of the investment projects [1]. Group 1 - The company held its 13th meeting of the second board and the 12th meeting of the second supervisory board on August 21, 2025 [1]. - The proposal allows the company to use its own funds for part of the investment project costs during the implementation period, with a plan to replace these funds with raised funds later [1]. - The supervisory board expressed clear agreement on this matter, and the sponsor institution provided verification opinions, indicating that this matter does not require submission to the shareholders' meeting for approval [1].

按申万行业统计，药康生物所属的医药生物行业共有32家公司公布了2025半年度分配方案，派现金额最 多的是药明康德，派现金额为10.03亿元，其次是东阿阿胶、华润三九，派现金额分别为8.17亿元、7.51 亿元。（数据宝） 2025半年度医药生物行业分红排名 | 代码 | 简称 | 每10股送转 | 每10股派现 | 派现金额（万 | | 派现占净利润比例 | 股息率 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | （股） | （元） | 元） | | （%） | （%） | | 603259 | 药明康 德 | 0.00 | 3.5 | 100308.38 | 11.72 | | 0.58 | | 000423 | 东阿阿 胶 | 0.00 | 12.69 | 81720.66 | 99.94 | | 2.20 | | 000999 | 华润三 九 | 0.00 | 4.5 | 75131.47 | 41.39 | | 1.10 | 8月22日药康生物发布2025半年度分配预案，拟10派0.3元（含税），预计派现金额合计为1226.97万元。 ...

Core Viewpoint - The company announced the appointment of Mr. Liu Dan as a non-independent director candidate and a member of the strategic committee of the second board of directors [1] Group 1 - The board of directors approved the election of Mr. Liu Dan [1]

Core Insights - The company reported a total operating revenue of 374,808,989.09 yuan for the first half of 2025, reflecting a year-on-year growth of 10.11% [1] - The net profit attributable to shareholders of the listed company was 70,905,477.14 yuan, showing a year-on-year decrease of 7.12% [1] Financial Performance - Operating revenue for the first half of 2025: 374.81 million yuan, up 10.11% compared to the previous year [1] - Net profit for the same period: 70.91 million yuan, down 7.12% year-on-year [1]

Core Insights - The company reported a revenue of 375 million yuan for the first half of 2025, representing a year-on-year growth of 10.11% [1] - The net profit attributable to shareholders decreased by 7.12% to 70.91 million yuan [1] - The net profit excluding non-recurring gains and losses increased by 14.75% to 62.93 million yuan [1] - Basic earnings per share were reported at 0.17 yuan [1] - The company plans to distribute a cash dividend of 0.30 yuan per 10 shares (including tax) to all shareholders [1]

江苏集萃药康生物科技股份有限公司 独立董事工作制度 第一章 总则 第一条为进一步完善江苏集萃药康生物科技股份有限公司（以下简称"公司" 或"本公司"）治理结构，促进公司规范运作，现就公司建立独立的外部董事（ 以下简称"独立董事"）制度，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司 独立董事管理办法》（以下简称"《管理办法》"）、《上市公司治理准则》《 上海证券交易所科创板股票上市规则》（以下简称"《科创板上市规则》"）等 有关法律、法规、规范性文件和《江苏集萃药康生物科技股份有限公司章程》（ 以下简称"公司章程"）的有关规定，特制定本制度。 第二章 一般规定 第二条独立董事是指不在公司担任除独立董事外的其他职务，并与其所受 聘的公司及公司主要股东不存在可能妨碍其进行独立客观判断的关系的董事。 第三条独立董事应按照法律、行政法规、中国证监会、上海证券交易所和 本章程的规定，认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨 询作用，维护公司整体利益，保护中小股东合法权益。 独立董事作为董事会的成员，对公司及全体股东负有忠实义务、勤勉义务 ...

江苏集萃药康生物科技股份有限公司 募集资金管理制度 第一章 总 则 第一条 为规范江苏集萃药康生物科技股份有限公司（以下简称"公司"） 募集资金的管理和使用，提高募集资金使用效率，最大限度地保护投资者利益， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所科 创板股票上市规则》（以下简称"《科创板上市规则》"）等法律、行政法规、 部门规章及规范性文件的相关规定以及《江苏集萃药康生物科技股份有限公司章 程》（以下简称"公司章程"）有关规定，特制定本制度。 第二条 本制度所称募集资金，是指公司通过向不特定对象发行证券（包括 首次公开发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换 公司债券等）以及向特定对象发行证券募集的资金，但不包括公司实施股权激励 计划募集的资金。 第三条 公司董事、高级管理人员应当勤勉尽责，督促公司规范使用募集资 金，自觉维护公司募集资金安全，不得参与、协助或纵容公司擅自或变相改变募 集资金用途。 第四条 公司控股股东、实际控制人不得直接或者间接占用或者挪用公司募 集资金，不得利用公司募集资金及募集资金投资项目（以下简称"募投项目"） 获取不正当利益。 第五 ...